Status:
ENROLLING_BY_INVITATION
Allergy Delabeling in Antibiotic Stewardship - Evaluations
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
University of Utah
Conditions:
Beta Lactam Allergy in Patients With a Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patients with a hematological malignancy.
Detailed Description
The RENEW clinical intervention is designed to evaluate the impact of a comprehensive beta lactam (BL) allergy delabeling intervention on clinical outcomes among patients hospitalized with a hematolog...
Eligibility Criteria
Inclusion
- Patient participants:
- a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
- a prior label applied to their medical record to indicate a beta lactam allergy
- hospitalized as an inpatient to an oncology service at the time the study is conducted
- Clinician participants:
- member of the primary inpatient care team
Exclusion
- Patient participants:
- meet one of the exclusionary criteria for the RENEW clinical intervention
- Clinician participants:
- no exclusions
Key Trial Info
Start Date :
December 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06967467
Start Date
December 1 2025
End Date
October 1 2029
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104